Abstract library

2 results for "Fantini".
#2168 Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors
Introduction: Activation of VEGFR2 and MET is implicated in driving growth of NET. Cabozantinib inhibits VEGFR2, MET, AXL, RET.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Jennifer Chan
Authors:
#1128 FDG PET as a Prognostic Factor in Pancreatic Neuroendocrine Tumors (P-NET) After Peptide Receptor Radionuclide Therapy with 177Lu-dotatate (Lu-PRRT).
Introduction: The best-known altered metabolism in cancer is an increased glycolysis. FDG-PET allow us to obtain in vivo imaging of this metabolic abnormality which is an hallmark of tumor aggressiveness.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini
Authors: